Investigational
Clinical Review
Women’s Health Clinic FAQ
Does the O-Shot really work?
Current clinical evidence indicates that autologous Platelet-Rich Plasma (PRP) is a promising investigational regenerative therapy for female sexual dysfunction (FSD) and stress urinary incontinence (SUI).
Direct answer
While pilot studies demonstrate positive subjective trends for sexual function and urinary continence, significant methodological differences and small sample sizes mean PRP cannot be viewed as a guaranteed cure. It remains an "off-label" application of autologous blood products, and its clinical efficacy should be balanced against established surgical standards.
Clinical progression is driven by the release of growth factors—specifically VEGF for neovascularization, TGF-β for collagen synthesis, and PDGF for tissue repair. However, individual results vary widely, and realistic expectations must be set.
Educational only. Evidence-based clinical overview for patients and practitioners. Results vary. Not a cure.
At a glance
The following performance markers define the current clinical baseline for PRP treatments.
Performance Metrics
Data extracted from recent meta-analyses
SUI Success
73.3% reduction in leakage
Sexual Function
Significant FSFI score improvements
Urodynamics
Increased leak point pressure
Quality of Life
80% improvement in ICIQ-SF scores
Urodynamic Limitation
Notably, urodynamic analysis shows no significant change in Functional Profile Length (FPL), suggesting the sphincteric seal's physical length remains unaffected despite pressure increases.
Collagen Synthesis
Neovascularization
Tissue Repair
Autologous
Detailed answer
Evaluating the Evidence
Understanding how PRP works at a cellular level provides insight into why it may be effective for some patients but not all.
Mechanism of Action
Clinical progression is driven by the release of growth factors that stimulate new tissue and skin development. However, while marketed as "instant," data suggests a 50/50 split; 50% of women perceive immediate results, while the remainder notice no changes on Day 0.
Angiogenesis
Tissue Regeneration
Variable Response
Early Phase (Days 3-7)
Patients may notice initial changes in sensation, arousal, or natural lubrication as the healing cascade begins.
Tissue Development (Week 1+)
Regeneration accelerates as growth factors stimulate new tissue and blood vessel development.
Peak Effect (Month 3)
Final clinical results for the session are typically achieved as cellular remodeling reaches maturity.
Longevity of Results
For patients who respond well, the clinical benefits typically persist for 14 to 18 months before a maintenance session may be required.
Evidence Limitations
High heterogeneity exists between preparation systems (e.g., RegenKit vs. TruPRP), meaning the concentration of platelets can vary significantly between clinics.
Furthermore, most studies are limited by small cohorts (n=15 to n=60), emphasizing the need for larger randomized controlled trials.
Patient safety
Why Proper Assessment Matters
Because PRP is an off-label treatment, comprehensive assessment is mandatory to ensure patient safety and suitability.
Regulatory Status
The O-Shot and generic vaginal PRP are not included in NICE or BSUG guidelines due to a lack of large-scale, long-term randomized controlled trials.
Informed Consent
Practitioners bear a heightened burden of disclosure. Patients must be explicitly informed that traditional surgical interventions remain the objective gold standard.
Institutional Oversight
Compliance with GMC, CQC, and MHRA standards regarding blood processing devices and autologous products is non-negotiable.
SUI Superiority
The Daneshpajooh RCT confirms that mid-urethral slings remain objectively superior to PRP for Stress Urinary Incontinence resolution.
Managing Expectations
Marketing claims must be meticulously separated from peer-reviewed outcomes. "O-Shot" is a commercial trademark for a specific injection protocol, not a magic bullet.
A full clinical assessment ensures we rule out underlying pathologies and understand if PRP is the most appropriate, safe choice for your individual symptoms.
Considerations
Clinical Protocols & Logistics
Preparation must follow standardized protocols to ensure a therapeutic concentration of platelets.
Concentration Yield
A standard venous draw of 40 mL of whole blood typically yields 2-4 mL of leukocyte-rich PRP when using advanced, medically-approved centrifugation systems.
Centrifugation
Buffy Coat
Activation
Blood Collection & Centrifugation
A standard venous draw (15-40 mL) is taken and spun in a centrifuge for 5-15 minutes to isolate the buffy coat containing the concentrated platelets.
Activation
Calcium Chloride may occasionally be added to initiate the thrombin cascade and form a fibrin matrix before injection.
Injection Protocol: FSD
For Female Sexual Dysfunction, approximately 2 mL of PRP is delivered to the distal anterior vaginal wall and periclitoral tissues.
Injection Protocol: SUI
For Stress Urinary Incontinence, 5-6 mL of PRP is delivered periurethrally into the submucosal plane.
The Patient Journey
The journey begins with a thorough assessment using validated questionnaires (FSFI/ICIQ-SF). On the day of the fast, office-based intervention (approx. 30 minutes), 2% Lidocaine gel is applied 20 minutes prior.
Systematic follow-up reviews at 1 week, 1 month, and 6 months monitor symptom relief and screen for adverse events.
Common concerns and myths
Debunking Efficacy Myths
Marketing often obscures the clinical realities of vaginal PRP.
Myth: It is a 100% guaranteed cure
Reality: Current evidence is "low." While many women experience significant subjective improvement, it is not a guaranteed cure, and surgical standards remain objectively superior for severe SUI.
Myth: Results are entirely instant
Reality: While 50% of women perceive immediate results, true tissue regeneration and neovascularization take weeks, reaching peak effect around month 3.
Myth: All PRP is the same
Reality: High heterogeneity exists between preparation systems. The efficacy depends heavily on the concentration of platelets achieved by the specific centrifuge device used.
Myth: It works for all incontinence
Reality: Pilot studies show promise primarily for mild-to-moderate stress urinary incontinence. It is not an established treatment for severe or urge incontinence.
Myth: O-Shot is a medical term
Reality: "O-Shot" is a commercial trademark. The broader medical study is "Periurethral/Vaginal PRP."
Safety checklist
Patient Safety & Expectations
Review this checklist to ensure you are fully prepared for the realities of off-label PRP treatment.
Realistic Timeline
Are you prepared to wait up to 3 months to judge the peak regenerative effects?
Surgical Alternatives
Have you been fully informed that traditional surgical interventions (like mid-urethral slings) remain the objective gold standard?
Off-Label Understanding
Do you understand that this remains an "off-label" application of autologous blood products?
Assessment Questionnaires
Are you willing to complete baseline validated questionnaires (FSFI/ICIQ-SF) to objectively measure progress?
Normal Recovery Signs
Documented instances of mild dysuria (discomfort when urinating), minor vaginal spotting, and temporary fullness are normal.
Mild Dysuria
Temporary Fullness
When to Seek Advice
While autologous, complications can rarely occur. You should contact the clinic if you experience severe pain, heavy bleeding, or inability to pass urine.
Urinary Retention
Heavy Bleeding
When to escalate
Adverse Events & When to Escalate
Because PRP uses your own blood, allergic reactions or rejection are virtually eliminated. However, any injection carries a small risk of infection or localized trauma. Be vigilant for the following symptoms. Contact Our Clinical Team
Severe or Worsening Pain
Mild tenderness is normal. However, if you experience severe, throbbing pain that worsens over time or is not relieved by paracetamol, you must seek clinical assessment.
Signs of Infection
If the area becomes hot to the touch, excessively swollen, or if you develop a fever or notice foul-smelling discharge, contact a doctor immediately as this may indicate a pelvic infection.
Heavy Bleeding
A few drops of blood or light spotting on toilet tissue is expected. Heavy bleeding (soaking a pad in an hour) is a medical emergency and requires urgent care.
Urinary Retention
There have been documented instances of temporary urinary retention (occasionally requiring short-term self-catheterization). If you cannot pass urine, seek emergency medical attention (A&E or 111).
If you experience chest pain, fainting, or severe shortness of breath, call 999 immediately. This guidance does not replace professional medical advice.
Additional Insights & Related Questions
What do the studies actually say?
A recent prospective pilot interventional study (Kochhar) showed a 73.3% reduction in urinary leakage episodes at 6 months and an 80% improvement in ICIQ-SF scores for mild-to-moderate SUI. Another study (Sukgen) showed significant improvements in the Female Sexual Function Index (FSFI), moving from a baseline of 14 to a post-treatment 28.Why isn't it available on the NHS?
The O-Shot® and generic vaginal PRP are not included in NICE or BSUG guidelines due to a lack of large-scale, long-term randomized controlled trials (RCTs). The NHS requires robust, long-term outcome data before adopting new therapies, and current evidence is still considered investigational.Can it cause hyper-arousal?
While extremely rare, there have been documented reports of "extreme sexual arousal" (spontaneous or continuous) following the procedure, linked to the nerve stimulation and increased blood flow.Regulatory resources
Authoritative UK Regulatory & Clinical Resources
For transparent, independent medical information regarding women's health, menopause, and clinical treatments, please refer to the following authoritative UK bodies.
NHS: Urinary Incontinence
Comprehensive NHS guidance on the diagnosis and established treatments for urinary incontinence.
NICE Guidelines: Urinary Incontinence
Official UK guidelines on the management of urinary incontinence and pelvic organ prolapse in women.
British Menopause Society
The specialist society providing evidence-based information on genitourinary syndrome of menopause (GSM) and sexual function.
Next step
Ready to discuss your options?
Our specialist clinicians provide discreet, comprehensive assessments to determine if the O-Shot is the right regenerative treatment for your vaginal health and wellbeing.
Research Evidence: CME Journal Geriatric Medicine (2026); Biomedicines (MDPI, 2023); Frontiers in Medicine (2026)
Educational only. All regenerative therapies carry individual variation in outcomes. Information provided does not constitute a medical diagnosis. Results vary. Not a cure.
